CClinicalTrials.gg
CompletedNCT06470893Updated Aug 19, 2025

Online Exposure Therapy for Obsessive-Compulsive Disorder (OCD) Study

An interventional study of OCD-NET in Obsessive-Compulsive Disorder, sponsored by University of Miami. Completed at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-08-19.

Sponsored by University of Miami · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
63
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The overarching goal of this protocol is to investigate mechanisms that influence symptom outcomes of exposure and response prevention (ERP) therapy for OCD. Mechanisms may include affective processes, learning factors, cognitive factors, or other constructs that could influence treatment outcomes. The study team will conduct this research within the context of an effective online treatment for OCD called OCD-NET. OCD-NET is bibliotherapy with coaching and its content is reflective of standard care for OCD.

02

Conditions studied

  • Obsessive-Compulsive Disorder
03

In context

Obsessive-Compulsive Disorder

606 studies on the registry are indexed under Obsessive-Compulsive Disorder; 160 are open to participants now.

This study's enrollment of 63 is above the median of 45 across 492 interventional studies indexed under Obsessive-Compulsive Disorder.

Browse Obsessive-Compulsive Disorder studies →

Lead sponsor

University of Miami is the lead sponsor of 820 studies on the registry; 161 are open to participants now.

Of its 111 completed or terminated interventional studies of FDA-regulated products, 93 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • English-speaking
  • Located within the United States
  • 18-90 years old
  • Able to provide consent
  • Current diagnosis of OCD as assessed by clinical interview

Exclusion criteria

Exclusion Criteria:

  • Adults unable to consent
  • Individuals who are not yet adults (infants, children, teenagers)
  • Participants currently located outside of the United States
  • Prisoners
  • Participants with hoarding as the primary OCD symptom
  • Severe mental illness (e.g. schizophrenia, substance abuse); organic brain syndrome; or serious, current suicidal/homicidal ideation (based on phone screening or initial assessment)
  • Concurrent enrollment in another psychotherapy treatment
  • Participants taking psychotropic medication may be excluded if:

    • They have started a brand new psychotropic medication within the last 12 weeks
    • They have changed the dose of their psychotropic medication within the last 4 weeks
    • They anticipate that they cannot maintain the current dose of their psychotropic medication for the duration of the study
  • Participants may be excluded if they have any cognitive or physical impairments that would interfere with their participation (e.g., significant head injury, cognitive disability, dementia).
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    OCD-NET Group

    Participants will receive the OCD-NET intervention for up to 12 months.

    Behavioral: OCD-NET

Interventions

  • BehavioralOCD-NET

    OCD-NET is bibliotherapy with coaching and its content is reflective of standard care for OCD. OCD-NET is a self-paced intervention that participants complete entirely online with the support of an assigned individual therapist. Most participants complete this treatment in up to twelve weeks. On average, participants are expected to spend between one to five hours per week during the first half of treatment. In the second half of treatment when participants begin regular exposure and response prevention (ERP) exercises, participants are expected to spend about one hour per day.

06

What researchers measure

Primary outcomes

  1. Change in OCD Symptoms Measured by Yale-Brown Obsessive Compulsive Scale-Second Edition (YBOCS-II)

    YBOCS-II scores range from 0-50, and higher scores indicate more severe illness

    Time frame: Baseline, up to 12 months (end of treatment)

07

Study locations

1 site
  • University of Miami
    Miami, Florida 33146, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06470893
Lead sponsor
University of Miami
Responsible party
Kiara Timpano (Professor, University of Miami) — Principal investigator
First posted
Jun 24, 2024
Start date
Sep 23, 2024
Primary completion
Jul 8, 2025
Completion
Jul 23, 2025
Last update
Aug 19, 2025

Study contacts

Kiara Timpano, PhD
study chair · University of Miami
Amelia Dev, MS
principal investigator · University of Miami

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion